Ariana Pelosci's profile photo

Ariana Pelosci

New York

Editor at Cancer Network

Editor @cancernetwrk | University of Delaware ‘21 | Author of Roxy and Velvet’s Big Adventure

Featured in: Favicon cancernetwork.com Favicon theodysseyonline.com Favicon newsbreak.com Favicon contemporaryobgyn.net Favicon onclive.com Favicon curetoday.com Favicon dermatologytimes.com Favicon targetedonc.com Favicon drugtopics.com Favicon urologytimes.com

Articles

  • Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

    1 week ago | cancernetwork.com | Ariana Pelosci

    On April 3, 2025, Steven Finkelstein, MD, DABR, FACRO, and his team were the first in the US to administer the recently approved lutetium Lu 177 (177Lu; Pluvicto) to a patient with metastatic castration-resistant prostate cancer (mCRPC).1 On March 28, 2025, the FDA gave extended approval to 177Lu for patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who have previously been treated with an androgen receptor pathway inhibitor (ARPI) and may be eligible to delay...

  • Social Detriments of Health Determine Acupuncture Expectancy in Breast Cancer

    1 week ago | cancernetwork.com | Ariana Pelosci

    Cultural perceptions, education, or financial status were found to shape attitudes surrounding acupuncture use as an integrative oncology therapy for patients who survived breast cancer, according to a poster presentation from the 2025 Oncology Nursing Society Congress.

  • FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

    1 week ago | cancernetwork.com | Ariana Pelosci |Tim Cortese

    The FDA has approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with unresectable or metastatic hepatocellular carcinoma, according to a press release from the agency.1The approval was based on results from the phase 3 CheckMate 9DW trial (NCT04039607) assessing nivolumab/ipilimumab vs lenvatinib (Lenvima) or sorafenib (Nexavar).

  • Female AYA Cancer Survivors May Benefit From Increased Physical Activity

    2 weeks ago | cancernetwork.com | Ariana Pelosci

    An increased need for vigorous physical activity programs among early adolescent and young adult survivors of cancer from the Childhood Cancer Survivor Study was highlighted in a recent study presented at the 2025 Oncology Nursing Society Congress. At baseline, 55% of patients achieved at least 6 metabolic equivalence tasks (MET) hours per week, 47% achieved it at timepoint 2, and 43% at timepoint 3.

  • Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

    2 weeks ago | cancernetwork.com | Ariana Pelosci

    Understanding auditory attention difficulties in pediatric patients with cerebellar tumors will help to improve the information surrounding cognitive late effects, psychosocial intervention, and pharmacological intervention, according to a poster presented at the 2025 American Psychosocial Oncology Society Meeting.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
42
Tweets
91
DMs Open
No
Ariana Pelosci
Ariana Pelosci @APelosci
9 Mar 24

RT @ginacolumbusonc: Great time in the Big Apple with some of our @OncLive and @CancerNetwrk crew at @gotoPER #NYGU today. Awesome work! 🙌🏻…

Ariana Pelosci
Ariana Pelosci @APelosci
8 Mar 24

It was great speaking with Dr. Taplin today during #NYGU! Excited to see CancerNetwork’s Women in Oncology program come together.

CancerNetwork®
CancerNetwork® @CancerNetwrk

It was a happy #InternationalWomensDay — we sat down with Dr Mary-Ellen Taplin of @DanaFarber to discuss her career in GU oncology! Keep your eye out for a brand new #womeninonc program 👀 #NYGU @gotoPER @APelosci #pcsm https://t.co/uvbciyxGiC

Ariana Pelosci
Ariana Pelosci @APelosci
10 Oct 23

It was great speaking with Dr. Gong about the upcoming @myESMO meeting. He gave a great overview on upcoming presentations, and which will be most impactful in the bladder and gastrointestinal space.

Jun Gong
Jun Gong @jgong15

Thank you @CancerNetwrk @APelosci! Always a pleasure catching up on latest GI/GU cancer breakthroughs especially with an exciting @myESMO 2023 fast approaching @CSCancerCenter @CedarsSinaiMed @CedarsSinai